Skip to main content
. 2017 Apr 5;7:61. doi: 10.3389/fonc.2017.00061

Figure 4.

Figure 4

IL-BCG induces tumor regressions in uninjected melanoma lesions. (A) IL-BCG induces regression of uninjected lesions. Upper left: in-transit melanoma metastases at the time of first IL-BCG treatment. Upper middle: 8 weeks post-IL-BCG, tumors exhibit mild to moderate inflammation. Upper right: 13 weeks post-IL-BCG. Adjacent uninjected tumors (white arrows) exhibiting regression (R) or non-regression (NR). (B) Presence of γδ T cells in regressed but not non-regressed uninjected melanoma lesions. (C) IFNγ secretion of tumor infiltrated by γδ T cells. Tumors infiltrated by γδ T cells secrete IFNγ isolated from regressed but not non-regressed uninjected melanoma lesions.